Evaluation of the safety of a coumarin-troxerutin combination.
Concerns about liver reactions reported for coumarin preparations prompted a re-evaluation of the combination of coumarin with troxerutin, widely used since 1971 in Germany. No evidence of liver toxicity could be found in available clinical research data. We estimated the number of coincidental cases of unexplained clinically apparent liver disease expected to arise during the patient treatment time on the basis of sales and the maximal recommended daily dosage. A comparison to the number of spontaneous reports yielded reassuring results.